関連する実験動画
Updated: Jun 12, 2026

05:53
Use of a Hanging-weight System for Liver Ischemia in Mice
Published on: August 7, 2012
16.5K
DRP1の枯渇はNK細胞を低酸素誘発機能障害から保護する
Tias Verhezen1, Astrid Van Den Eynde1, Peter Verstraelen2
1Center for Oncological Research (CORE), Integrated Precision and Personalized Oncology Network (IPPON), University of Antwerp, Antwerpen, Belgium.
Redox report : communications in free radical research
|February 18, 2026
まとめ
低酸素症は,固体腫瘍における自然殺傷細胞 (NK細胞) の機能を損なう. DRP1タンパク質を非活性化すると,NK細胞のミトコンドリアと細胞毒性の活性が低毒状態で回復し,CAR-NK細胞の有効性を高めます.
科学分野:
- 免疫学 免疫学とは
- 細胞生物学 細胞生物学
- がん研究 がん研究
背景:
- 細胞治療は,固体腫瘍では,主に免疫抑制性腫瘍の微小環境のために,限られた有効性を示しています.
- 腫瘍低酸素症は,がんに対する先天免疫の重要な構成要素である自然殺傷細胞 (NK) の機能を著しく低下させます.
研究 の 目的:
- 低酸素がNK細胞の機能に与える影響を調査する.
- 低酸素状態下でNK細胞の活動を回復するための戦略を評価する.
主な方法:
- NK細胞 (無武装またはCAR-エンジニアリング) は,ノルモキシアまたはヒポキシアで培養されました.
- ミトコンドリア機能,ROS生成,遺伝子発現を分析した.
- 細胞毒性アッセイは,がん細胞系と患者由来オーガノイドに対して実施されました.
- DRP1の機能は,薬理学的抑制またはCRISPR-Cas9ノックアウトによって調節された.
主要な成果:
- 低酸素症はNK細胞のミトコンドリア含有量と膜ポテンシャルを低下させ,ROSを増加させ,遺伝子発現を変化させた.
- 細胞毒性活性が著しく低下し,CAR工学でもその効果は認められた.
- DRP1の阻害またはノックアウトにより,ミトコンドリア機能が回復し,低酸素状態でNK細胞の細胞毒性が保たれた.
- DRP1ノックアウトCAR NK細胞は,低酸素状態でもがん細胞系に対する有効性を維持した.
結論:
- DRP1不活性化は,低毒性腫瘍マイクロ環境におけるNK細胞機能を強化するための有効な戦略です.
- DRP1を標的とする代謝工学のアプローチは,固体腫瘍に対するCAR-NK細胞治療を改善する可能性がある.
関連する概念動画
Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Directing Proteins to the Rough Endoplasmic Reticulum
The organelle-specific signaling sequences direct proteins synthesized in the cytosol to their final destination like ER, mitochondria, peroxisomes, etc. Some of the proteins directed to ER are then trafficked via vesicles to other organelles within the cell or the extracellular environment through the Golgi complex. For example, the rough ER synthesizes soluble proteins for transportation to the lysosomes or secretion out of the cell. It can also synthesize transmembrane proteins that can...
The Unfolded Protein Response
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
Export of Misfolded Proteins out of the ER
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
Regulation of the Unfolded Protein Response
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

